Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report shows strong financial performance with 25% revenue growth and a shift to net income, indicating effective cost management. Positive cash flow and strategic initiatives in clinical development and partnerships further support a positive sentiment. Despite no updates on dividends or buybacks, the financial health and strategic outlook are favorable. No significant concerns were raised in the Q&A, reinforcing the positive sentiment.
Key Financial Performance
Revenue Zymeworks reported a revenue of $75 million for Q4 2025, which represents a 25% increase year-over-year. This growth was primarily driven by the successful launch of a new product line and increased market penetration.
Net Income The company achieved a net income of $10 million, compared to a net loss of $5 million in Q4 2024. This improvement was attributed to higher revenues and cost optimization measures implemented during the year.
Operating Expenses Operating expenses were $50 million, up 10% year-over-year. The increase was due to higher R&D investments and expansion of the sales team.
Cash Flow Zymeworks generated a positive cash flow of $15 million in Q4 2025, a significant improvement from a negative cash flow of $2 million in the same period last year. This was due to improved operational efficiency and higher revenue collection.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties. This includes risks associated with the company's industry and stage of development.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: Forward-looking statements are based upon our current expectations and various assumptions and are subject to risks and uncertainties, including those associated with the company in our industry and at our stage of development. For a discussion of these risks and uncertainties, I refer you to the latest SEC filings as found on
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
dividend program: No specific mention of a dividend program in the provided text.
shares buyback program: No specific mention of a shares buyback program in the provided text.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acting CFO
Acting Chief
Adam Schayowitz
Asthika Goonewardene
Benjamin Citizens
Bijal Desai
CEO Acting
CFO President
Chief Investment
Chief Medical
Citizens JMP
Desai Senior
Division Asthika
Division EST
Division Eva
Division Ionov
Division Jonathan
Division Mayank
Division Reni
EST conference
Eva Fortea
Fargo Securities
Finance Sabeen
Goonewardene Truist
Inc Research
Investor Relations
LLC Research
Research Division
Securities Inc
Securities LLC
Shrinal Inamdar
ZYME Transcript
Capstone Copper Corp. (CS:CA) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlights strong financial performance with increased revenue, net income, and EBITDA. Strategic initiatives in expanding copper production and targeting renewable energy markets are promising. The company anticipates revenue growth and improved margins, despite some regulatory and economic risks. Lack of shareholder return plans is a downside, but overall, the positive financial metrics and strategic outlook suggest a favorable stock price reaction.
Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings report shows strong financial performance with 25% revenue growth and a shift to net income, indicating effective cost management. Positive cash flow and strategic initiatives in clinical development and partnerships further support a positive sentiment. Despite no updates on dividends or buybacks, the financial health and strategic outlook are favorable. No significant concerns were raised in the Q&A, reinforcing the positive sentiment.
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
ZYME Slides
ZYME Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
